<DOC>
	<DOCNO>NCT02957604</DOCNO>
	<brief_summary>This prospective observational registry study evaluate fetal , infant childhood outcome woman expose evolocumab pregnancy</brief_summary>
	<brief_title>Evolocumab Pregnancy Exposure Registry</brief_title>
	<detailed_description>This pregnancy registry conduct University California Research Center Organization Teratology Information Specialists ( OTIS ) network university health department base telephone information center serve pregnant woman healthcare provider throughout North America . Participants enrol ongoing basis year 10 study follow time enroll , 5-year postnatal follow period overall study period 15 year . Participants recruit concurrently caller OTIS center , healthcare provider direct consumer marketing effort .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>For group : Qualified subject agree condition requirement study include interview schedule , release medical record , physical examination live bear infant , 5 year followup . For Specific EvolocumabExposed Cohort : Currently pregnant woman ( maternal report validate medical record ) diagnose hypercholesterolemia ASCVD , hypercholesterolemia associate FH expose evolocumab number day , dose , time first day LMP include end pregnancy . For Comparison Group I : Currently pregnant woman ( maternal report validate medical record ) diagnose hypercholesterolemia ASCVD , hypercholesterolemia associate FH expose evolocumab pregnancy time within 90 day prior first day LMP . For Comparison Group II : Currently pregnant woman diagnose hypercholesterolemia ASCVD , hypercholesterolemia associate FH expose evolocumab pregnancy time within 90 day prior first day LMP , exposure know human teratogen determine OTIS Research Center For General EvolocumabExposed Case Series group : Women exposure evolocumab pregnancy meet criterion Specific EvolocumabExposed cohort reason include ( limited ) : ASCVD hypercholesterolemia and/or hypercholesterolemia associate FH ( offlabel use ) , expose evolocumab pregnancy already complete , enrol cohort study previous pregnancy , already prenatal diagnosis major birth defect For group except General Evolocumab Exposed Case Series Group : Women first contact Registry prenatal diagnosis major structural defect Women expose different PCSK9 inhibitor current pregnancy time within 5 halflives prior first day LMP Women enrol Registry previous pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pregnancy ; Cardiovascular Diseases ; High serum cholesterol</keyword>
</DOC>